Photo by jontyson from unsplash
Emicizumab markedly shortens the activated partial thromboplastin time (aPTT), resulting in inaccurate measurements of procoagulant and anticoagulant factor activities. We have recently reported that mixtures of two different anti‐idiotype monoclonal… Click to show full abstract
Emicizumab markedly shortens the activated partial thromboplastin time (aPTT), resulting in inaccurate measurements of procoagulant and anticoagulant factor activities. We have recently reported that mixtures of two different anti‐idiotype monoclonal antibodies against emicizumab (anti‐emicizumab‐mAbs) allow measurement of factor (F)VIII activity (FVIII:C) and FVIII inhibitor in emicizumab‐containing plasmas. It is unknown whether anti‐emicizumab mAbs can work for other aPTT‐based procoagulant and anticoagulant assays.
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!